In millions, except per share items | Dec-29-17 | Dec-30-16 | Jan-01-16 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 |
| 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K |
Revenues: |
Home Health | 586.1 | 435.0 | 400.1 | | | | | |
Other Home-based Services | 184.8 | 162.5 | 128.6 | | | | | |
Healthcare Innovations | 26.1 | 26.0 | 3.5 | 2.5 | 0.2 | | | |
Other Home Based Care | | | | 112.5 | 92.9 | 89.0 | 56.3 | 40.4 |
Other | | | | 380.8 | 263.8 | 251.6 | 275.2 | 294.9 |
Total revenues | 797.0 | 623.5 | 532.2 | 495.8 | 356.9 | 340.6 | 331.4 | 335.3 |
Revenue growth [+] | 27.8% | 17.2% | 7.3% | 38.9% | 4.8% | 2.8% | -1.1% | 13.3% |
Home Health | 34.7% | 8.7% | | | | | | |
Other Home-based Services | 13.7% | 26.4% | | | | | | |
Healthcare Innovations | 0.4% | 654.2% | 35.7% | 1198.0% | | | | |
Other Home Based Care | | | | 21.1% | 4.4% | 58.2% | 39.3% | 1.1% |
Visiting Nurse | | | | 44.4% | 4.8% | -8.6% | -6.7% | 15.2% |
Cost of goods sold | 419.4 | 335.5 | 281.8 | 264.0 | 190.5 | 176.7 | 163.1 | 152.5 |
Gross profit | 377.6 | 288.1 | 250.4 | 231.8 | 166.4 | 163.9 | 168.3 | 182.8 |
Gross margin | 47.4% | 46.2% | 47.0% | 46.8% | 46.6% | 48.1% | 50.8% | 54.5% |
Selling, general and administrative [+] | 667.3 | 493.4 | 430.7 | 269.2 | 196.8 | 175.4 | 175.6 | 170.9 |
Sales and marketing | 223.0 | 168.4 | 147.8 | | 45.2 | 39.4 | 39.9 | 39.8 |
General and administrative [+] | 444.3 | 325.1 | 282.9 | 269.2 | 151.6 | 136.0 | 135.7 | 131.1 |
Wages and related expenses | 223.0 | 168.4 | 147.8 | 139.8 | 102.0 | 96.0 | 95.1 | 91.3 |
General and administrative expenses | 348.4 | 252.6 | 217.4 | 207.2 | 151.6 | 136.0 | 135.7 | 131.1 |
Other selling, general and administrative | 223.0 | 168.4 | 147.8 | | 45.2 | 39.4 | 39.9 | 39.8 |
Other operating expenses | -318.9 | -240.8 | -213.3 | -62.1 | -45.2 | -39.4 | -39.9 | -39.8 |
EBITDA [+] | 35.1 | 39.9 | 36.9 | 28.6 | 17.7 | 30.5 | 35.4 | 54.6 |
EBITDA growth | -11.9% | 8.2% | 29.0% | 61.9% | -42.1% | -13.9% | -35.0% | 23.3% |
EBITDA margin | 4.4% | 6.4% | 6.9% | 5.8% | 4.9% | 9.0% | 10.7% | 16.3% |
Depreciation | 5.2 | 3.8 | 3.9 | 3.9 | 2.9 | 2.6 | 2.8 | 2.9 |
EBITA | 29.9 | 36.1 | 32.9 | 24.7 | 14.8 | 28.0 | 32.6 | 51.7 |
EBITA margin | 3.8% | 5.8% | 6.2% | 5.0% | 4.1% | 8.2% | 9.9% | 15.4% |
Amortization of intangibles | 0.7 | 0.7 | | | | | | |
EBIT [+] | 29.2 | 35.4 | 32.9 | 24.7 | 14.8 | 28.0 | 32.6 | 51.7 |
EBIT growth | -17.6% | 7.6% | 33.6% | 66.7% | -47.1% | -14.4% | -36.8% | 23.4% |
EBIT margin | 3.7% | 5.7% | 6.2% | 5.0% | 4.1% | 8.2% | 9.9% | 15.4% |
Interest expense | 7.4 | 6.3 | 2.9 | 1.6 | 0.2 | 0.1 | 0.2 | 0.3 |
Interest expense | 7.4 | 6.3 | 2.9 | 1.6 | 0.2 | 0.1 | 0.2 | 0.3 |
Pre-tax income | 21.8 | 29.2 | 30.1 | 23.0 | 14.6 | 27.8 | 32.5 | 51.4 |
Income taxes | -2.1 | 11.0 | 10.6 | 9.5 | 6.0 | 11.0 | 12.8 | 20.7 |
Tax rate | | 37.7% | 35.1% | 41.3% | 41.2% | 39.7% | 39.5% | 40.2% |
Minority interest | -3.5 | -0.5 | 0.5 | 0.2 | 0.2 | | | |
Earnings from continuing ops | 20.4 | 17.7 | 20.0 | 13.8 | 8.8 | 16.8 | 19.6 | 30.7 |
Earnings from discontinued ops | | | | | -0.6 | 0.5 | 1.2 | |
Net income | 20.4 | 17.7 | 20.0 | 13.8 | 8.2 | 17.3 | 20.8 | 30.7 |
Net margin | 2.6% | 2.8% | 3.8% | 2.8% | 2.3% | 5.1% | 6.3% | 9.2% |
|
Basic EPS [+] | $1.51 | $1.74 | $2.11 | $1.47 | $0.95 | $1.81 | $2.12 | $3.37 |
Growth | -13.3% | -17.4% | 42.8% | 55.8% | -47.7% | -14.5% | -37.1% | 14.7% |
Diluted EPS [+] | $1.48 | $1.71 | $2.05 | $1.45 | $0.94 | $1.80 | $2.10 | $3.28 |
Growth | -13.0% | -16.9% | 41.2% | 55.2% | -48.0% | -14.1% | -36.1% | 14.8% |
|
Dividends per share [+] | $0.01 | | $0.01 | $0.00 | | $2.00 | | |
Growth | | -100.0% | 40.3% | | -100.0% | | | |
|
Shares outstanding (basic) [+] | 13.5 | 10.2 | 9.5 | 9.3 | 9.3 | 9.3 | 9.3 | 9.1 |
Growth | 33.3% | 6.8% | 1.8% | 0.6% | -0.1% | 0.1% | 1.7% | 9.0% |
Shares outstanding (diluted) [+] | 13.8 | 10.3 | 9.7 | 9.5 | 9.4 | 9.3 | 9.4 | 9.4 |
Growth | 33.0% | 6.2% | 3.0% | 0.9% | 0.5% | -0.4% | 0.1% | 8.9% |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |